#obesity treatment
Total 3 articles
EconomyEN
Novo Nordisk's Obesity Drug Stumble: What It Means for Your Wallet
Novo Nordisk's CagriSema disappoints in trials against Eli Lilly's obesity treatments. Analysis of the trillion-dollar market battle and implications for patients and investors.
·
SP
Seoyeon Park
EconomyEN
Lilly Bets $1.5B on Weight-Loss Pills Before FDA Says Yes
Eli Lilly stockpiles $1.5 billion of oral Zepbound ahead of FDA approval, signaling confidence in weight-loss pill market disruption
·
SP
Seoyeon Park
EconomyEN
No More Yo-Yo: Japan's New Obesity Drug Targets Rebound Weight Gain
Chugai Pharmaceutical and Roche develop next-generation obesity treatment designed to prevent weight regain after stopping medication. Approval targeted for 2028 in competitive market.
·
SP
Seoyeon Park
PRISM by Liabooks
PRISM
Advertise with Us
Place your ad in this space
[email protected]